Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.55 |
| ▸ | RAB9A | P51151 | 8/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.55 |
| ▸ | NPC1 | O15118 | 6/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 5/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4166440 | 0.88 | MAPT (0.52) | MAPTALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL20452290 | 0.88 | ALDH1A1 (0.65) | MAPTALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL4161700 | 0.80 | RAB9A (0.53) | MAPTALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL4159119 | 0.79 | ALDH1A1 (0.58) | MAPTALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL20452073 | 0.79 | ALDH1A1 (0.58) | MAPTALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL4161633 | 0.74 | ALDH1A1 (0.53) | MAPTALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL4173588 | 0.73 | PTGS2 (0.38) | MAPTALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL14955176 | 0.72 | ALDH1A1 (0.61) | MAPTALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL2076090 | 0.72 | ALDH1A1 (0.61) | MAPTALDH1A1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL5159248 | 0.72 | PTGS2 (0.37) | MAPTALDH1A1RAB9ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CDK2, CDK4, CDK20 | MAPT 2054/4885ALDH1A1 2743/4885RAB9A 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.